bevacizumab + carboplatin + dulanermin + paclitaxel

This drug is a combination therapy consisting of four agents used primarily in oncology, notably investigated as a first-line treatment for advanced or recurrent non-small-cell lung cancer (NSCLC). - Bevacizumab is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood supply. - Carboplatin is a platinum-based small molecule chemotherapy agent that causes DNA crosslinking and apoptosis. - Dulanermin is a recombinant human Apo2L/TRAIL protein that induces apoptosis by activating death receptors on tumor cells. - Paclitaxel is a microtubule-stabilizing small molecule chemotherapy agent that inhibits cell division. The combination has been studied to evaluate efficacy and safety, with clinical trials showing no significant improvement in outcomes when dulanermin was added to bevacizumab, carboplatin, and paclitaxel in unselected NSCLC patients. Bevacizumab combined with carboplatin and paclitaxel alone has FDA approval for first-line treatment of unresectable, locally advanced, recurrent or metastatic nonsquamous NSCLC based on improved overall survival[1][3].

Brand names

Avastin (bevacizumab)others vary by component but no unique brand for combination